Board of Directors

Meet our board

Rob Binney
Executive Chairman
Rob Binney is the Chief Executive Officer of ShiraTronics and a 25-year veteran executive of the medical device and pharmaceutical industries. Prior to joining ShiraTronics, Rob served as the CEO of Alydia Health. During his tenure, Alydia was able to close a $13.9M Series C round of financing and received 510(k) Clearance of the Jada System. Rob holds a BA in Communications from the University of North Carolina at Chapel Hill. [LinkedIn]
Kaushal Solanki
Kaushal Solanki
Founder and CEO
Kaushal Solanki, Ph.D., is the Founder and CEO of Eyenuk, Inc., where he sets the vision for the company and leads the product development and market execution. Kaushal pioneered the development, prospective clinical validation, regulatory process, and commercialization of the EyeArt® system for the autonomous detection of diabetic retinopathy. Kaushal has a doctorate in Electrical and Computer Engineering from the University of California, Santa Barbara, and has published widely in international journals, with his work cited over 1500 times. He holds several issued and pending patents. [LinkedIn]
Zina Affas Besse
Dr. Zina Affas Besse is the Deputy Head of Healthcare Private Equity at AXA IM Alts, a global leader in alternative investments. She serves as a Board Member for Biolinq and Axena Health. She holds a Ph.D. in Medicinal Chemistry and Pharmacy degrees from The University of Nottingham. [LinkedIn]
Billede - Copy
Marie-Louise Little
Marie-Louise Little is currently the Director of Strategy and Business Development at TW Medical A/S in Denmark and has 23 years of operational, strategic, and investment experience in Life Sciences bringing medical technologies and companies from idea to market and also serves on the board of directors for Optheras A/S, Human Bytes, MyBlueLabel Compliance Services, and Biolinq. of holding board positions at five other medical technology companies. She holds a BA in Biomedical Materials Science from the University of Birmingham and an MSc in Medical Engineering from the University of Liverpool. [LinkedIn]
Manish Potti
Manish Potti is currently the Chief Business Officer of Shinkei Therapeutics, a CNS focused company and serves on the board of directors of Ocugen Inc. (OCGN) and Solaris Pharma Inc. He holds a B.S. in Cellular and Molecular Biology from Johns Hopkins University and a M.S. in Financial Engineering from New York University. [LinkedIn]